The Hinge Drug Discovery Platform provides a mechanism for discovering novel compound and has shown to find solutions for traditionally “undruggable” targets.

Utilizing advanced AI techniques, and coupled with a unique patented methodology, we have improved the efficiency and success rate of identifying possible hit compounds for a range of important diseases.

This approach is also useful as a drug repositioning tool. We are currently investigating several targets which are indicated for oncology, drug resistance, hypertension, and Alzheimer’s disease.

• Evaluation of the target based on the sequence information, mutation, known and proprietary induced protein conformational change
• Design molecules which trigger functional conformational change and validate the approach

• Proprietary Hinge-Focused library which acts on Hinge and induces functional conformational change to affect PPI/act as inhibitor

• Biophysical analysis to determine the in vitro SAR
• Ex vivo model combined with proprietary Ion image sensor technology evaluate the efficacy and safety of the compounds.

Our approach enables the discovery of seemingly weak binding yet specific conformational modulators that other platforms cannot find.

We believe the specificity often comes from intrinsic properties of the target and not from the drug itself. This approach allows us to explore new “druggability” and leads to drug repositioning and discovery of new compounds.

Hinge Therapeutics and Toyohashi University of Technology, Japan are collaborating to validate and expedite drug development data.  Together with the Japanese government (JST), Hinge Therapeutics is collaborating and commercializing proprietary ion image sensor technology from Toyohashi University of Technology. 

Hinge Therapeutics has obtained the exclusive rights to use the technology from this collaboration.